



IN THE U.S. PATENT AND TRADEMARK OFFICE

Atty Docket No. 107.823.129

In Re

Application of: Madiyalakan et al.

) Art Unit: 1642

Serial Number: 09/376,604

) Examiner: M. Tran

Filed: August 18, 1999

For: THERAPEUTIC COMPOSITIONS
THAT ALTER THE IMMUNE
RESPONSE

)
)
)

13
KO
6-1/51

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an enveloped addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on the date indicated below.

May 30, 2001

Date of Signature and of Mail Deposit

Dina Haves

Diana Havens

Commissioner for Patents
Washington, D.C. 20231


SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit herewith the references listed on the attached form PTO 1449, copies of which are enclosed. The submission of this statement is not a representation that a search has been made, or that no better art exists. This submission is also not an admission that any of the cited references is, or is considered to be, material to patentability or that any of the cited references constitutes prior art to the invention.

This statement is being filed before the receipt of the first office action. Accordingly, no fees are believed to be due at this time.

Applicant reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application. If it should be determined that any of the listed documents do not constitute prior art under United States law, Applicant reserves the right to present to the Officer the relevant facts and law regarding the appropriate status of such documents.

It is respectfully requested that the Examiner initial and return copies of the enclosed form PTO-1449 with the next Patent Office communication.



Supplemental Information Disclosure Statement
Page 2 of 2
09/376,604

No additional fees are believed to be due in connection with this submission. However, please apply any additional charges, or credit any overpayment, to our Deposit Account No. 08-0219.

Respectfully submitted,
HALE AND DORR LLP

Date: May 30, 2001

Nancy Chiu
Nancy Chiu, Ph.D.
Registration No. 43,545
Agent for Applicants

60 State Street
Boston, MA 02109
(617) 526-6000
(617) 526-5000 (fax)



Gp1642

IN THE U.S. PATENT AND TRADEMARK OFFICE
Atty Docket No. 107.823.129

RECEIVED
JUN 07 2001

TECH CENTER 1600/2900

In Re
Application of: Madiyalakan et al.) Art Unit: 1642
Serial Number: 09/376,604) Examiner: M. Tran
Filed: August 18, 1999)
For: THERAPEUTIC COMPOSITIONS)
THAT ALTER THE IMMUNE)
RESPONSE)

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an enveloped addressed to: Commissioner for Patents, Washington, DC 20231 on the date indicated below.

May 30, 2001
Date of Signature and of Mail Deposit

Diana Havens
Diana Havens

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Dear Sir:


Enclosed for filing are the following documents:

1. Supplemental Information Disclosure Statement;
2. PTO form 1449 and copies of 2 (two) references;
3. Return postcard.

Transmittal Letter
09/376,604

No fees are believed to be due with this communication; however, please charge any additional fees or credit any overpayment associated with this matter to our Deposit Account No. 08-0219.

Respectfully submitted,
HALE AND DORR LLP



Nancy Chiu, Ph.D.
Registration No. 43,545
Agent for Applicants

Date: May 30, 2001
60 State Street
Boston, MA 02109
(617) 526-6000
(617) 526-5000 (fax)